Skip to main content

Mangoceuticals, Inc.

corporate_fare Company Profile

Mangoceuticals, Inc.

MGRX·NASDAQ·Industrial Applications And Services·CIK 0001938046

Mangoceuticals, Inc. develops, markets, and sells men's wellness products and services in the United States, primarily through a telemedicine platform. The company offers erectile dysfunction products under the Mango brand, hair loss products under the Grow brand, hormone balance and therapy products under the Mojo brand, and weight loss products under the Slim brand. It also provides oral testosterone undecanoate, marketed under the Prime brand, to treat low testosterone in men and for testosterone replacement therapy. Mangoceuticals facilitates customer access to a licensed pharmacy for online fulfillment and distribution of medications prescribed during telehealth consultations. The company markets and sells its products online via its website, www.MangoRX.com. Incorporated in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as a subsidiary of Cohen Enterprises, Inc.

Mangoceuticals, Inc. (NASDAQ:MGRX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for MGRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Mangoceuticals Reprices CEO Options, Files $73M Lawsuit Against Former Consultant
  • Mangoceuticals Sues Former Tech Firm for $73M+ Over Failed Platform Delivery
  • Mangoceuticals Seeks Patent Expansion for MGX-0024 Antiviral to Cover Animal and Bird Infections
  • Mangoceuticals' MGX-0024 Shows Strong Antiviral Efficacy in Poultry Trials, H5N1 Study
  • Mangoceuticals Reports 336% MoM Sales Growth for Injectable TRT Program, Cuts Customer Acquisition Costs by 54%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$456.02K
Net Income
-$20.64M
Diluted EPS
-$2.17
Op. Cash Flow
-$5.85M
Gross Profit
$250.39K
Operating Income
-$18.03M
Cash & Equivalents
$1.49M
Debt / Equity
0.00×
Net Margin
-45.27×
Shares Outstanding
15.89M sh
Source: 10-K · filed 2026-04-01 · accession 0001493152-26-014478
$0.124 +0.32% today
52-week range · as of 2026-11-16 $0.124 – $1.49
Market cap
$2.75M
Volume
241.3K (0.3× avg)
3-mo avg 711.6K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MGRX - Filings & News (Page 2)

MGRX
Mar 17, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4005
Real-time Price: $0.124 info
Change: -$0.2765 (-69%) info
Market Cap: $2.747M info
MGRX
Mar 17, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.4676
Real-time Price: $0.124 info
Change: -$0.3436 (-73%) info
Market Cap: $2.747M info
MGRX
Mar 06, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.520
Real-time Price: $0.124 info
Change: -$0.396 (-76%) info
Market Cap: $2.747M info
MGRX
Feb 23, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4855
Real-time Price: $0.124 info
Change: -$0.3615 (-74%) info
Market Cap: $2.747M info
MGRX
Feb 19, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4966
Real-time Price: $0.124 info
Change: -$0.3726 (-75%) info
Market Cap: $2.747M info
MGRX
Feb 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.382
Real-time Price: $0.124 info
Change: -$0.258 (-68%) info
Market Cap: $2.747M info
MGRX
Jan 23, 2026, 5:07 PM EST
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.5383
Real-time Price: $0.124 info
Change: -$0.4143 (-77%) info
Market Cap: $2.747M info
MGRX
Jan 13, 2026, 5:30 PM EST
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.7202
Real-time Price: $0.124 info
Change: -$0.5962 (-83%) info
Market Cap: $2.747M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets